GlassScriptPhysician profile
Leslie Ann Harry
NPI 1477576932
$2,900.36
in general payments reported to CMS, 2019-2025
42 companies · $2,390 in 2025
The $2,390 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $85.95 · 2023: $84.99 · 2024: $339 · 2025: $2,390.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,509 · Education: $305.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,509.44 |
| Education | $304.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $266.02 | 2024-2025 | |
| Glaxosmithkline, LLC. | $171.92 | 2024-2025 | Ojjaara, Blenrep |
| Abbvie INC. | $164.46 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $155.52 | 2023-2025 | Keytruda, Welireg, Keytruda Qlex |
| Janssen Biotech, INC. | $154.06 | 2024-2025 | Talvey, Tecvayli, Erleada |
| Seagen INC. | $139.98 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $137.01 | 2022-2024 | Opdivo |
| Astrazeneca Pharmaceuticals LP | $132.44 | 2024-2025 | Imfinzi, Enhertu |
| Incyte Corporation | $121.39 | 2025 | Jakafi, Niktimvo, Monjuvi |
| Genzyme Corporation | $114.69 | 2025 | |
| Daiichi Sankyo INC. | $108.52 | 2025 | Datroway, Vanflyta, Enhertu |
| Genmab U.S., INC. | $104.62 | 2024-2025 | Epkinly, Tivdak |
| Exelixis INC. | $99.99 | 2025 | |
| Pfizer INC. | $90.56 | 2025 | |
| Lilly USA, LLC | $74.82 | 2025 | Jaypirca, Verzenio, Retevmo |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leslie Harry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.